Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib

MT Newswires Live06-01

Agios Pharmaceuticals (AGIO) secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.

Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.

Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.

Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640953136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640953136","market":"sg","top_or_hot":-1,"title":"Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib","media":"MT Newswires Live","content":"<html><body><p> Agios Pharmaceuticals (AGIO) secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.</p><p>Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.</p><p>Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.</p><p>Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-01 18:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Agios Pharmaceuticals (AGIO) secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.</p><p>Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.</p><p>Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.</p><p>Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640953136","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640953136","pubTimestamp":1780309879,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Agios Pharmaceuticals  secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"Agios Pharmaceuticals与Oscotec签署Cevidoplenib全球许可协议","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1.5},"content_text":"Agios Pharmaceuticals (AGIO) secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640953136","isCrawlerRequest":true}